Compositions Against Cancer Antigen Liv-1 and Uses Thereof
Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.
1 . A murine antibody that specifically binds a polypeptide or protein encoded by SEQ ID NO:1, wherein the antibody is selected from the group of Table 6.
2 . An antibody which is a chimeric or humanized form of the murine antibody of claim 1 .
3 . The antibody of claim 2 , which is a chimeric or humanized form of the antibody 1.7A4, BR2-13a or BR2-19a.
4 . The antibody of claim 2 , which is a chimeric or humanized form of the antibody 1.7A4.
5 . The antibody of claim 4 , wherein the chimeric antibody comprises a heavy chain variable region having the amino acid sequence of SEQ ID NO:3 and a light chain variable region having the amino acid sequence of SEQ ID NO:4.
6 . The antibody of claim 4 , wherein the humanized antibody comprises a heavy chain variable region having the amino acid sequences of the complementarity determining regions of SEQ ID NO:3 and a light chain variable region having the amino acid sequences of the complementarity determining regions of SEQ ID NO:4.
7 . The antibody of claim 2 , which is a chimeric or humanized form of the antibody 1.1F10.
8 . The antibody of claim 2 , which is a chimeric or humanized form of the antibody BR2-14a, BR2-15a, BR2-16a, BR2-20a, BR2-21a, BR2-22a, BR2-23a, BR2-24a or BR2-25a.
9 . The antibody of claim 2 , wherein the chimeric or humanized antibody is conjugated to an effector component.
10 . The antibody of claim 9 , wherein the effector component is selected from the group consisting of a fluorescent label, a radioisotope or a cytotoxic chemical.
11 . The antibody of claim 10 , wherein the cytotoxic chemical is auristatin-E or MMAE.
12 . The antibody of claim 2 , wherein the chimeric or humanized antibody is an antibody fragment.
13 . A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the antibody of claim 2 .
14 . The pharmaceutical composition of claim 13 , wherein the antibody is conjugated to an effector component.
15 . The pharmaceutical composition of claim 14 , wherein the effector component is selected from the group consisting of a fluorescent label, a radioisotope or a cytotoxic chemical.
16 . The pharmaceutical composition of claim 16 , wherein the cytotoxic chemical is auristatin-E or MMAE.
17 . A method of treating an individual with prostate or breast cancer, the method comprising administering a therapeutically effective dose of the chimeric or humanized antibody of claim 2 .
18 . The method of claim 17 , wherein the antibody is a chimeric antibody.
19 . The method of claim 17 , wherein the antibody is an antibody fragment.
20 . The method of claim 17 , wherein the antibody is a humanized antibody.
21 . The method of claim 17 , wherein the antibody is conjugated to an effector component.
22 . The method of claim 21 , wherein the effector component is selected from the group consisting of a fluorescent label, a radioisotope or a cytotoxic chemical.
23 . A hybridoma producing the antibody of claim 2 .
24 . The hybridoma of claim 23 , wherein the hybridoma is selected from the group consisting of ATCC accession number PTA-5705, ATCC accession number PTA-5706 and ATCC accession number PTA-5707.